Importantly, IDH1 mutation confers a distinctive survival advantage in glioma patients; large cohort studies confirmed a 2-fold increase of median overall survival in glioblastoma patients and a more than threefold increase in lower-grade glioma patients compared with their respective controls46,47. Here, IDH1 is linked to glioblastoma.